

FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMPI31-FSCA

Date: DD MM YYYY

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.

# <u>Urgent Field Safety Notice</u> <u>Rocket KCH™ Fetal Bladder Drain R57405</u> <u>Destroy Device</u>

For Attention of: Persons responsible for medical device vigilance / risk management Clinicians in the fetal medicine department Distributors

**Contact details of local representative:** For further information, please contact: Regulatoryaffairs@rocketmedical.com ROCKET MEDICAL PLC SEDLING ROAD WASHINGTON TYNE & WEAR NE38 9BZ ENGLAND 
 TEL:
 +44
 191
 419
 4488

 FAX:
 +44
 191
 419
 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

## <u>Urgent Field Safety Notice</u> <u>Rocket KCH™ Fetal Bladder Drain R57405</u> <u>Destroy Device</u> <u>Non-medical grade material used</u>

	I. Information on Affected Devices	
I	I. Device Type(s)	
	Rocket KCH <sup>™</sup> Fetal Bladder Drain Procedure kit is a sterile, single-use device intended to create a fetal-amniotic shunt to treat fetal lower urinary tract outflow obstruction by allowing the urine to flow from the baby's bladder into the amniotic sac, bypassing the urinary tract. The device contains a double pigtail stent with an outer tube diameter of 2.1mm and inner tube diameter of 1.5mm.	
	Fetal coil Maternal coil	
I	2. Commercial name(s)	
	Rocket KCH™ Fetal Bladder Drain	
	Rocket KCH™ Fetal Bladder Catheter	
	3. Unique Device Identifier(s) (UDI-DI)	
	R57405	
	4. Primary clinical purpose of device(s)	
	The device is indicated for use in fetal bladder decompression following the diagnosis of fetal	
	post-vesicular obstructive uropathy in fetuses of 18-32 weeks gestation.	
I	5. Device Model/Catalogue/part number(s)	
	R57405	
I         6. Software version           N/A – This device is not software and nor does it incorporate software.		
		I
	00000000475024, 00000000479735, 00000000482145, 00000000488912.	
I	8. Associated devices	
	N/A – There are no other devices associated with this FSN.	

	2. Reason for Field Safety Corrective Action (FSCA)		
2	I. Description of the product problem		
	An error has been made on the part of our supplier in which non-medical grade material was		
	provided and used in manufacture instead of the medical grade material ordered.		
2	2. Hazard giving rise to the FSCA		
	Following discovery of the mistake, sales of the product were suspended and biological safety		
	testing (cytotoxicity) was undertaken on a device made with the incorrect material. The results		
	of this testing demonstrated that an extract of the non-medical grade material gives a positive		

 
 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com
 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

#### FSCA Ref: INTCOMP131-FSCA

	result in an <i>in vitro</i> cytotoxicity test. Whilst not demonstrated, this means that we cannot rule out		
	the risk of in vivo toxicity.		
2	3. Probability of problem arising		
	A positive cytotoxicity test is not, on its own, indicative of a toxic effect in clinical use. Rather,		
	is an indication of the need for further evaluation. To date, no incidents have been reported		
	because of this issue.		
2	4. Predicted risk to patient/users		
	The results of <i>in vitro</i> cytotoxicity tests cannot be interpreted directly in terms of clinical risk until		
	further information is obtained. It is therefore not possible to estimate the risk to patients.		
2	5. Further information to help characterise the problem		
	Cytotoxicity tests are routinely used as screening tests in the biological evaluation of medical		
	devices. A positive result means that an extract of the device led to a toxic response in a		
	proportion of cultured mammalian cells. This does not necessarily mean that a toxic effect will		
	occur upon clinical use, but this possibility cannot be ruled out. Therefore, a decision to destroy		
	all devices that have not yet been implanted has been made.		
2	6. Background on Issue		
	No incidents have been reported as a consequence of this issue.		
	An error has been made on the part of our supplier in which non-medical grade material was		
	provided and used instead of the medical grade material ordered. Sales of the product were		
	suspended whilst testing was undertaken, which has since revealed a positive result for in vitro		
	cytotoxicity. Whilst not demonstrated, this means that we cannot rule out the risk of in vivo		
	toxicity. Medical grade material has now been procured, but further testing is being undertaken		
	to confirm conformity before this device is returned to the market.		
2	7. Other information relevant to FSCA		
	Sales of the device continue to be suspended. Upon the advice of the German Regulatory Body,		
	BfArM, this field safety corrective action is being implemented to destroy any unused product on		
	the market. The Rocket KCH™ Fetal Bladder Drain has a five-year shelf life but is commonly		
	used within one year of manufacture. The total number of devices considered to have been		
	affected by this issue is 2474 units, although it is likely that the majority have been used and we		
1	estimate only 854 to remain on the global market.		

		3. Type of Action to mitigate the risk		
3	١.	Action To Be Taken by the User		
		□ Identify Device □ Quarantine Device □ Return Device ⊠ Destroy Device		
		□ On-site device modification/inspection		
		□ Follow patient management recommendations		
		$\Box$ Take note of amendment/reinforcement of Instructions For Use (IFU)		
		□ Other □ None		
	Without delay, identify any KCH™ Fetal Bladder Drains / KCH Fetal Bladder Catheters (REF R57405) in stock. Note: all devices within shelf life are affected by this issue. Destroy			



FSN Ref: INTCOMP131-FSN

#### FSCA Ref: INTCOMP131-FSCA

	all devices not yet implanted. Rocket Medical will replace or reimburse all destroyed devices.			
	Please confirm that you have received this communication and undertaken the required actions by completing and returning the attached "Customer Response" form.			
	Ensure relevant staff members are informed of this action, including locums. If this device has been transferred/supplied to another facility or organisation, please let them know of the action immediately by providing a copy of this FSN.			
		No action is recommended for	or devices already implanted (pleas	se see justification below).
	If users are concerned about the impact of the non-availability of the device for the treatment of a particular patient, they should inform Rocket Medical who will put them in touch with the appropriate regulatory authority. All questions should be directed to Rocket Medical PLC through the email address Regulatoryaffairs@rocketmedical.com.			
3	2.	By when should the action be completed?	Immediately and without delay.	
3	3.	Particular considerations	for: implantable device	
	Is follow-up of patients or review of patients' previous results recommended? No. Justification: The device is critical for the pre-natal survival of the fetus already implanted with this device. Any potential remedial action, such as replacing the device with an alternative or expediting delivery, is considered to carry greater risk than leaving implanted devices in situ.			
3		Is Customer Reply Requir		Yes
3	(Please complete and return applicable form(s).) 5. Action Being Taken by the Manufacturer			
		<ul> <li>☑ Product Removal</li> <li>□ Software upgrade</li> <li>□</li> </ul>	On-site device modification/inspection IFU or labelling change None	n
	Further actions, including additional testing, are being undertaken to allow return of the device to the market. It is anticipated that compliant devices will become available from 23 November 2020.			
3	6.	By when should the	As soon as possible.	ironi 25 November 2020.
		action be completed?	·	
3	7.	Is the FSN required to be patient /lay user?	communicated to the	No
3	8.	If yes, has manufacturer p	provided additional informatio nt/lay or non-professional user	
	N//	A		

 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



#### FSN Ref: INTCOMP131-FSN

#### FSCA Ref: INTCOMP131-FSCA

	4. General Information		
4	I. FSN Type	New	
4	2. For updated FSN, reference number and date of previous FSN	N/A – This is a new FSN.	
4	3. For Updated FSN, key new info	rmation as follows:	
	N/A – This is a new FSN.		
4	4. Further advice or information	N/A – Follow-up FSN not expected.	
	already expected in follow-up FSN?		
	5. If follow-up FSN expected, what	is the further advice expected to relate to:	
4	N/A – Follow-up FSN not expected.		
4	6. Anticipated timescale for follow-up FSN	N/A – Follow-up FSN not expected.	
4	7. Manufacturer information		
	(For contact details of local representative re		
	a. Company Name	Rocket Medical PLC	
	b. Address	Sedling Road, Washington, Tyne & Wear, NE38 9BZ, England	
	c. Website address	www.rocketmedical.com	
4	8. The Competent (Regulatory) Authority of your country has been informe		
	about this communication to cu	stomers.	
4	9. List of attachments/appendices:	- Customer Response Form	
4.	10. Name/Signature		
		Duth Chambre	
		Ruth Sharples Head of Quality and Regulatory Affairs	
		Rocket Medical PLC	

Transmission of this Field Safety Notice		
This notice needs to be passed on to all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)		
Please transfer this notice to other organisations on which this action has an impact. (As appropriate)		
Please maintain awareness of this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.		
Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.		

 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

#### FSCA Ref: INTCOMP131-FSCA

### **Customer Response Form**

I. Field Safety Notice (FSN) information	
FSN Reference number	INTCOMP131-FSN
FSN Date	DD MM YYYY
Product/ Device name	Rocket KCH™ Fetal Bladder Drain
Product Code(s)	R57405
Batch/Serial Number (s)	00000000475024, 00000000479735,
	00000000482145, 000000000488912.

2. Customer Details		
Healthcare Organisation Name		
Organisation Address		
Department/Unit		
Contact Name		
Title or Function		
Telephone number		
Email		

3. C	3. Customer action undertaken on behalf of Healthcare Organisation		
	I confirm receipt of the	Comment	
	Field Safety Notice and		
	that I read and		
	understood its content.		
	I have/will perform all	Comment	
	actions requested by the FSN.		
	The information and	Comment	
	required actions have		
	been brought to the		
	attention of all relevant		
	users.		
	I have destroyed the	Number of devices:	
	following number of		
	devices:		
	The Batch/Serial Number	Serial / LOT number (required for replacement / reimbursement):	
	(SN or LOT) for devices		
	destroyed are:		
	I do not have any affected	Comment	
	devices.		
Print N			
Signati	ure		
Date			

4. Return acknowledgement to:	
Email	regulatoryaffairs@rocketmedical.com
Subject of e-mail	"INTCOMP131-FSN Response"

 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



#### FSN Ref: INTCOMP131-FSN

#### FSCA Ref: INTCOMP131-FSCA

Deadline for returning the Customer Response	Immediately / As soon as possible.
form	